Open Payments

MAZEN A HANNA

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
Where
INDEPENDENCE, OH
NPI
1033128731
Received
$257,295 in 163 records, 2019 to 2025 ($207,845 general, $49,450 research)
As principal investigator
$1,404,162 of research payments to others in 88 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment37$46,995
2025Research payment12$12,570
2024General payment31$60,161
2024Research payment8$7,790
2023General payment22$35,815
2023Research payment7$11,370
2022General payment6$13,676
2022Research payment5$6,030
2021General payment2$3,600
2021Research payment2$1,270
2020General payment5$28,980
2020Research payment9$10,420
2019General payment17$18,617

By company

CompanyRecordsAmountYears
PFIZER INC.73$146,9362019–2025
Alnylam Pharmaceuticals Inc.37$69,4012019–2025
Alexion Pharmaceuticals, Inc.11$18,1792022–2025
AstraZeneca Pharmaceuticals LP9$5,9352022–2024
AstraZeneca UK Limited4$4,6022024–2025
Novo Nordisk AS1$3,7502022
Akcea Therapeutics, Inc.1$3,1752020
Novo Nordisk Inc1$3,1002024
Abbott Laboratories6$4392023–2025
Impulse Dynamics (USA) Inc.3$3312023–2025
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)3$2132019–2023
CVRx, Inc.1$1682025
Paragonix Technologies, Inc.3$1602024
ABIOMED2$1482019–2025
BridgeBio Pharma, Inc.1$1432025
Boehringer Ingelheim Pharmaceuticals, Inc.1$1242019
E.R. Squibb & Sons, L.L.C.1$1242023
scPharmaceuticals Inc.1$1152025
Lilly USA, LLC2$912019
Life Molecular Imaging Ltd1$902022
Kestra Medical Technology Services, Inc.1$622023

By nature of payment

NatureRecordsAmount
Consulting Fee33$114,145
Research payment43$49,450
Travel and Lodging24$40,369
Honoraria6$33,065
Compensation for services other than consulting, including serving as faculty or as a speaker at a v8$16,092
Food and Beverage49$4,173

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-16Abbott Laboratories$90Food and BeverageIn-kind items and servicesTHORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Structural Heart2025
2025-12-11Alexion Pharmaceuticals, Inc.$1,050Consulting FeeCash or cash equivalent2025
2025-12-09PFIZER INC.$5,200Consulting FeeCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2025
2025-12-09PFIZER INC.$2,600Consulting FeeCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2025
2025-12-08PFIZER INC.$1,820Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-12-02PFIZER INC.$780Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-11-27PFIZER INC.$3,200Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-11-20AstraZeneca UK Limited$650Consulting FeeCash or cash equivalentWAINUA Drug, Cardiovascular and Metabolism2025
2025-11-19PFIZER INC.$14Food and BeverageIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2025
2025-10-15Alexion Pharmaceuticals, Inc.$8,050Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-02PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-09-29Alexion Pharmaceuticals, Inc.$610Travel and LodgingIn-kind items and services2025
2025-09-28PFIZER INC.$64Food and BeverageIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2025
2025-09-26Alexion Pharmaceuticals, Inc.$968Travel and LodgingIn-kind items and services2025
2025-09-23PFIZER INC.$780Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-09-19Alnylam Pharmaceuticals Inc.$1,319Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2025
2025-09-19AstraZeneca UK Limited$1,300Consulting FeeCash or cash equivalent2025
2025-09-17PFIZER INC.$39Food and BeverageIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2025
2025-09-05BridgeBio Pharma, Inc.$143Food and BeverageIn-kind items and servicesAttruby Drug, Cardiomyopathy2025
2025-08-30AstraZeneca UK Limited$52Food and BeverageIn-kind items and services2025
2025-08-29PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-08-29PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-08-29Alexion Pharmaceuticals, Inc.$24Food and BeverageIn-kind items and services2025
2025-08-27Alnylam Pharmaceuticals Inc.$448Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2025
2025-08-27Alnylam Pharmaceuticals Inc.$407Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2025
2025-08-27Alnylam Pharmaceuticals Inc.$407Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2025
2025-08-19Alnylam Pharmaceuticals Inc.$356Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2025
2025-08-18Alnylam Pharmaceuticals Inc.$11,665Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2025
2025-08-13PFIZER INC.$780Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-08-12Alnylam Pharmaceuticals Inc.$902Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAMVUTTRA Drug, Genetic Disease2025
2025-08-12Alnylam Pharmaceuticals Inc.$115Food and BeverageIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2025
2025-07-31Alnylam Pharmaceuticals Inc.$149Food and BeverageIn-kind items and servicesONPATTRO Drug, Genetic Disease2025
2025-06-25Alexion Pharmaceuticals, Inc.$1,050Consulting FeeCash or cash equivalent2025
2025-05-17PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-05-13ABIOMED$126Food and BeverageIn-kind items and services2025
2025-04-17PFIZER INC.$3,200Consulting FeeCash or cash equivalentVYNDAMAX Drug, CARDIOVASCULAR2025
2025-04-14CVRx, Inc.$168Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-04-10Impulse Dynamics (USA) Inc.$27Food and BeverageCash or cash equivalentOptimizer Device, Cardiovascular Device2025
2025-04-02PFIZER INC.$886Travel and LodgingCash or cash equivalent2025
2025-03-29PFIZER INC.$508Travel and LodgingIn-kind items and servicesVYNDAMAX Drug, CARDIOVASCULAR2025
2025-03-29Alexion Pharmaceuticals, Inc.$90Food and BeverageIn-kind items and services2025
2025-03-21Alexion Pharmaceuticals, Inc.$700Consulting FeeCash or cash equivalent2025
2025-03-20Alexion Pharmaceuticals, Inc.$875Consulting FeeCash or cash equivalent2025
2025-02-28PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-02-28PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-02-28scPharmaceuticals Inc.$115Food and BeverageIn-kind items and servicesFUROSCIX Drug, Cardiology2025
2025-02-19PFIZER INC.$1,400Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2025
2025-02-12Alnylam Pharmaceuticals Inc.$148Food and BeverageIn-kind items and services2025
2025-01-16Alnylam Pharmaceuticals Inc.$2,467Consulting FeeCash or cash equivalentONPATTRO Drug, Genetic Disease2025
2024-12-31PFIZER INC.$6,500Consulting FeeCash or cash equivalentVYNDAMAX Drug, CARDIOVASCULAR2024
2024-12-30PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARVYNDAQEL CLINICAL PUBLICATION PROGRAM2024
2024-12-19PFIZER INC.$8,448Consulting FeeCash or cash equivalentVYNDAMAX Drug, CARDIOVASCULAR2024
2024-12-17PFIZER INC.$3,200Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARVYNDAQEL CLINICAL PUBLICATION PROGRAM2024
2024-12-09PFIZER INC.$3,200Consulting FeeCash or cash equivalentVYNDAMAX Drug, CARDIOVASCULAR2024
2024-12-04Novo Nordisk Inc$3,100Consulting FeeCash or cash equivalent Biological2024
2024-11-29PFIZER INC.$3,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBENEFIX Biological, HEMATOLOGY2024
2024-11-27Alnylam Pharmaceuticals Inc.$5,557Consulting FeeCash or cash equivalent2024
2024-11-18PFIZER INC.$1,216Travel and LodgingIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2024
2024-11-16PFIZER INC.$40Food and BeverageIn-kind items and services2024
2024-10-28Abbott Laboratories$136Food and BeverageIn-kind items and servicesCARDIOMEMS Device, Heart Failure2024
2024-10-22AstraZeneca UK Limited$2,600Consulting FeeCash or cash equivalent2024
2024-10-17PFIZER INC.$3,248Consulting FeeCash or cash equivalentVYNDAMAX Drug, CARDIOVASCULAR2024
2024-10-09AstraZeneca Pharmaceuticals LP$120Food and BeverageIn-kind items and servicesFARXIGA Drug, Cardiovascular and Metabolism2024
2024-10-04Alnylam Pharmaceuticals Inc.$2,820Consulting FeeCash or cash equivalentAMVUTTRA Drug, Genetic Disease2024
2024-10-03PFIZER INC.$2,600HonorariaCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2024
2024-09-30PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2024
2024-08-30PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2024
2024-08-29PFIZER INC.$51Food and BeverageIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2024
2024-07-17Abbott Laboratories$24Food and BeverageIn-kind items and servicesCARDIOMEMS Device, Heart Failure2024
2024-06-27Impulse Dynamics (USA) Inc.$130Food and BeverageCash or cash equivalentOptimizer Device, Cardiovascular Device2024
2024-05-26PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARVYNDAQEL CLINICAL PUBLICATION PROGRAM2024
2024-05-17Abbott Laboratories$1Food and BeverageIn-kind items and servicesTHORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure2024
2024-05-08AstraZeneca Pharmaceuticals LP$96Food and BeverageIn-kind items and servicesLOKELMA Drug, Cardiovascular and Metabolism2024
2024-04-19Alnylam Pharmaceuticals Inc.$2,291Consulting FeeCash or cash equivalent2024
2024-04-11Paragonix Technologies, Inc.$142Food and BeverageIn-kind items and services2024
2024-04-11Paragonix Technologies, Inc.$15Food and BeverageIn-kind items and services2024
2024-04-11Paragonix Technologies, Inc.$1Food and BeverageIn-kind items and services2024
2024-04-04Alnylam Pharmaceuticals Inc.$9,366Travel and LodgingCash or cash equivalent2024
2024-03-11PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARVYNDAQEL CLINICAL PUBLICATION PROGRAM2024
2024-02-28PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2024
2024-01-26PFIZER INC.$780Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2024
2024-01-24AstraZeneca Pharmaceuticals LP$96Food and BeverageIn-kind items and services2024
2024-01-18Alnylam Pharmaceuticals Inc.$4,680Consulting FeeCash or cash equivalentAMVUTTRA Drug, Genetic Disease2024
2024-01-18AstraZeneca Pharmaceuticals LP$125Food and BeverageIn-kind items and servicesFARXIGA Drug, Cardiovascular and Metabolism2024
2024-01-18AstraZeneca Pharmaceuticals LP$6Food and Beverage (3 payments)In-kind items and servicesFARXIGA Drug, Cardiovascular and Metabolism2024
2024-01-12Alnylam Pharmaceuticals Inc.$122Food and BeverageIn-kind items and servicesONPATTRO Drug, Genetic Disease2024
2024-01-11Alnylam Pharmaceuticals Inc.$107Food and BeverageIn-kind items and servicesONPATTRO Drug, Genetic Disease2024
2024-01-10Alnylam Pharmaceuticals Inc.$111Food and BeverageIn-kind items and servicesONPATTRO Drug, Genetic Disease2024
2023-12-15PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2023
2023-12-12PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2023
2023-12-07PFIZER INC.$3,200Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2023
2023-11-21AstraZeneca Pharmaceuticals LP$2,148Consulting FeeCash or cash equivalent2023
2023-11-04Alnylam Pharmaceuticals Inc.$301Travel and LodgingCash or cash equivalentAMVUTTRA Drug, Genetic Disease2023
2023-11-04Alnylam Pharmaceuticals Inc.$249Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2023
2023-11-03Alnylam Pharmaceuticals Inc.$239Travel and LodgingCash or cash equivalentAMVUTTRA Drug, Genetic Disease2023
2023-11-02Alnylam Pharmaceuticals Inc.$370Consulting FeeCash or cash equivalentAMVUTTRA Drug, Genetic Disease2023
2023-11-02Alnylam Pharmaceuticals Inc.$249Travel and LodgingCash or cash equivalentAMVUTTRA Drug, Genetic Disease2023
2023-11-01Alnylam Pharmaceuticals Inc.$217Travel and LodgingCash or cash equivalentAMVUTTRA Drug, Genetic Disease2023
2023-11-01Abbott Laboratories$6Food and BeverageIn-kind items and servicesTHORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure2023
2023-10-31Alnylam Pharmaceuticals Inc.$9,435Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2023
2023-10-31Alnylam Pharmaceuticals Inc.$264Travel and LodgingIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2023
2023-10-31Alnylam Pharmaceuticals Inc.$245Travel and LodgingCash or cash equivalentAMVUTTRA Drug, Genetic Disease2023
2023-10-10PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2023
2023-10-09AstraZeneca Pharmaceuticals LP$119Food and BeverageIn-kind items and services2023
2023-10-06PFIZER INC.$43Food and BeverageIn-kind items and servicesVYNDAMAX Drug, CARDIOVASCULAR2023
2023-09-07AstraZeneca Pharmaceuticals LP$1,611Consulting FeeCash or cash equivalent2023
2023-08-15PFIZER INC.$8,820Consulting FeeCash or cash equivalent2023
2023-08-07PFIZER INC.$3,200Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2023
2023-07-31PFIZER INC.$5,300HonorariaCash or cash equivalent2023
2023-07-20Impulse Dynamics (USA) Inc.$173Food and BeverageCash or cash equivalentOPTIMIZER Device, Cardiovascular Device2023
2023-06-06E.R. Squibb & Sons, L.L.C.$124Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2023
2023-05-11PFIZER INC.$780Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2023
2023-04-26Kestra Medical Technology Services, Inc.$62Food and BeverageCash or cash equivalentAssure WCD Device, Cardiology2023
2023-04-01PFIZER INC.$3,200Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2023
2023-03-27Abbott Laboratories$179Food and BeverageIn-kind items and servicesMITRACLIP Device, Vascular2023
2023-03-15ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$95Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2023
2023-03-02Alnylam Pharmaceuticals Inc.$5,557Consulting FeeCash or cash equivalentONPATTRO Drug, Genetic Disease2023
2022-12-14AstraZeneca Pharmaceuticals LP$1,611Consulting FeeCash or cash equivalent2022
2022-12-08Life Molecular Imaging Ltd$90Food and BeverageCash or cash equivalentNEURACEQ Drug, Diagnostic Tracer2022
2022-08-19PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS MEGLUMINE CLINICAL PUBLICATION PROGRAM2022
2022-08-04PFIZER INC.$3,465HonorariaCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2022
2022-08-03Alexion Pharmaceuticals, Inc.$2,520Consulting FeeCash or cash equivalent2022
2022-06-20Novo Nordisk AS$3,750Consulting FeeCash or cash equivalentTresiba Drug, Diabetes2022
2022-06-14PFIZER INC.$780Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2022
2022-05-11Alexion Pharmaceuticals, Inc.$2,240Consulting FeeCash or cash equivalent2022
2022-05-03PFIZER INC.$780Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2022
2022-04-21PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2022
2022-02-07PFIZER INC.$3,200Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2022
2021-11-15PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2021
2021-10-11PFIZER INC.$3,500HonorariaCash or cash equivalent2021
2021-10-07ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$100Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2021
2021-06-10PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2021
2020-12-31PFIZER INC.$5,000HonorariaCash or cash equivalent2020
2020-11-09Alnylam Pharmaceuticals Inc.$3,510Consulting FeeCash or cash equivalentONPATTRO Drug, Genetic Disease2020
2020-10-06PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2020-09-18PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2020-09-18PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2020-09-01PFIZER INC.$940Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2020-08-06PFIZER INC.$13,200HonorariaCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2020
2020-07-02Alnylam Pharmaceuticals Inc.$4,095Consulting FeeCash or cash equivalentONPATTRO Drug, Genetic Disease2020
2020-06-25PFIZER INC.$1,400Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2020-06-18Akcea Therapeutics, Inc.$3,175Consulting FeeCash or cash equivalent2020
2020-05-16PFIZER INC.$3,200Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2020-04-20PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2020-04-07PFIZER INC.$1,400Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2020-02-14PFIZER INC.$330Research paymentIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULARTAFAMIDIS CLINICAL PUBLICATION PROGRAM2020
2019-12-30PFIZER INC.$1,400Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2019
2019-12-03PFIZER INC.$330Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2019
2019-11-27PFIZER INC.$330Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2019
2019-11-13Lilly USA, LLC$73Food and BeverageIn-kind items and servicesJARDIANCE Drug, Diabetes2019
2019-11-13Lilly USA, LLC$17Food and BeverageIn-kind items and servicesJARDIANCE Drug, Diabetes2019
2019-10-10Boehringer Ingelheim Pharmaceuticals, Inc.$124Food and BeverageIn-kind items and servicesJARDIANCE Drug, DIABETES2019
2019-10-02ABIOMED$22Food and BeverageIn-kind items and servicesImpella Device, Cardiology/Vascular Diseases2019
2019-09-16PFIZER INC.$940Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2019
2019-09-16PFIZER INC.$940Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2019
2019-09-13Alnylam Pharmaceuticals Inc.$115Food and BeverageIn-kind items and servicesONPATTRO Drug, Genetic Disease2019
2019-08-26PFIZER INC.$13,200Consulting FeeCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2019
2019-05-20Alnylam Pharmaceuticals Inc.$100Food and BeverageIn-kind items and servicesONPATTRO Drug, Genetic Disease2019
2019-03-29ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$17Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2019
2019-01-30Alnylam Pharmaceuticals Inc.$135Travel and LodgingIn-kind items and services2019
2019-01-29Alnylam Pharmaceuticals Inc.$377Travel and LodgingIn-kind items and services2019
2019-01-29Alnylam Pharmaceuticals Inc.$357Travel and LodgingIn-kind items and services2019
2019-01-29Alnylam Pharmaceuticals Inc.$135Travel and LodgingIn-kind items and services2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-22Eidos Therapeutics, Inc.Cleveland Clinic Hospital$2,128An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin 2025
2025-10-31Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$6,137A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATI2025
2025-10-24Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$4,622AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT2025
2025-10-03Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$20,282AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT2025
2025-10-02Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$5,860A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATI2025
2025-09-12Eidos Therapeutics, Inc.Cleveland Clinic Hospital$1,755An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin 2025
2025-09-01Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$4,075A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATI2025
2025-08-20Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$4,845AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT2025
2025-07-28Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$14,627AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT2025
2025-07-28Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$16,629A PHASE 3 GLOBAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION682884 IN PATI2025
2025-07-25Alexion Pharmaceuticals, Inc.Cleveland Clinic Hospital$384,242a phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid dep2025
2025-07-17Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$22,145An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis2025
2025-07-01Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$2,336An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis2025
2025-06-25Ionis Pharmaceuticals, Inc.Cleveland Clinic Hospital$6,934AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT2025
2025-05-20Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$585An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis2025
2025-05-15Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$11,895An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis2025
2023-12-14Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$390Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy2023
2023-11-29Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$24,800Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy2023
2023-10-27Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$84,900Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy2023
2023-10-27Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$17,050Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy2023
2023-09-08Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$3,190Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy2023
2023-08-24PFIZER INC.Cleveland Clinic Hospital$958A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 202023
2023-07-26American RegentCleveland Clinic Hospital$1,835Heart_FID2023
2023-07-03American RegentCleveland Clinic Hospital$200Heart_FID2023
2023-06-15Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$390Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy2023
2023-06-14American RegentCleveland Clinic Hospital$2,662Heart_FID2023
2023-04-12Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$58,486Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy2023
2023-03-27Alnylam Pharmaceuticals Inc.Cleveland Clinic Hospital$23,250Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy2023
2023-03-06American RegentCleveland Clinic Hospital$333Heart_FID2023
2023-01-19American RegentCleveland Clinic Hospital$5,275Heart_FID2023
2022-12-05American RegentCleveland Clinic Hospital$333Heart_FID2022
2022-11-09American RegentCleveland Clinic Hospital$1,814Heart_FID2022
2022-10-17American RegentCleveland Clinic Hospital$800Heart_FID2022
2022-09-08American RegentCleveland Clinic Hospital$333Heart_FID2022
2022-08-03American RegentCleveland Clinic Hospital$5,308Heart_FID2022
2022-04-20American RegentCleveland Clinic Hospital$2,600Heart_FID2022
2022-03-23PFIZER INC.Cleveland Clinic Hospital$2,500A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 202022
2022-03-07American RegentCleveland Clinic Hospital$333Heart_FID2022
2022-01-24American RegentCleveland Clinic Hospital$1,100Heart_FID2022
2021-12-08American RegentCleveland Clinic Hospital$2,647Heart_FID2021
2021-10-20American RegentCleveland Clinic Hospital$5,708Heart_FID2021
2021-07-14American RegentCleveland Clinic Hospital$3,200Heart_FID2021
2021-06-07American RegentCleveland Clinic Hospital$433Heart_FID2021
2021-06-04PFIZER INC.Cleveland Clinic Hospital$234A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 202021
2021-04-22PFIZER INC.Cleveland Clinic Hospital$234A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 202021
2021-04-14American RegentCleveland Clinic Hospital$2,708Heart_FID2021
2021-01-23PFIZER INC.Cleveland Clinic Hospital$600A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 202021
2021-01-22PFIZER INC.Cleveland Clinic Hospital$4,668A PHASE 3 MULTICENTER OPENLABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE PF0629182683 202021
2021-01-11American RegentCleveland Clinic Hospital$1,533Heart_FID2021
2020-12-23PFIZER INC.Cleveland Clinic Hospital$1,735A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-11-09American RegentCLEVELAND CLINIC FOUNDATION$2,347Heart_FID2020
2020-10-15American RegentCLEVELAND CLINIC FOUNDATION$7,350Heart_FID2020
2020-09-18PFIZER INC.Cleveland Clinic Hospital$25,872A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-08-10American RegentCLEVELAND CLINIC FOUNDATION$333Heart_FID2020
2020-07-08American RegentCLEVELAND CLINIC FOUNDATION$1,400Heart_FID2020
2020-04-08American RegentCLEVELAND CLINIC FOUNDATION$14,950Heart_FID2020
2020-04-02PFIZER INC.Cleveland Clinic Hospital$1,500A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-04-02PFIZER INC.Cleveland Clinic Hospital$5,100A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-04-02PFIZER INC.Cleveland Clinic Hospital$2,400A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-04-02PFIZER INC.Cleveland Clinic Hospital$1,200A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-03-17PFIZER INC.Cleveland Clinic Hospital$234A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-03-09American RegentCLEVELAND CLINIC FOUNDATION$933Heart_FID2020
2020-03-05PFIZER INC.Cleveland Clinic Hospital$3,500A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-03-02PFIZER INC.Cleveland Clinic Hospital$66,500A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-02-12American RegentCLEVELAND CLINIC FOUNDATION$3,909Heart_FID2020
2020-02-06PFIZER INC.Cleveland Clinic Hospital$219,990A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2020
2020-01-13American RegentCLEVELAND CLINIC FOUNDATION$7,475Heart_FID2020
2019-12-12PFIZER INC.CLEVELAND CLINIC HOSPITAL$11,000A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-12-12PFIZER INC.CLEVELAND CLINIC HOSPITAL$234A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-10-09American RegentCLEVELAND CLINIC FOUNDATION$15,600Heart_FID2019
2019-09-17PFIZER INC.CLEVELAND CLINIC HOSPITAL$116,774A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-09-17PFIZER INC.CLEVELAND CLINIC HOSPITAL$26,225A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-09-16American RegentCLEVELAND CLINIC FOUNDATION$333Heart_FID2019
2019-09-10PFIZER INC.CLEVELAND CLINIC HOSPITAL$61,958A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-08-01PFIZER INC.CLEVELAND CLINIC HOSPITAL$234A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-08-01PFIZER INC.CLEVELAND CLINIC HOSPITAL$100A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-07-18PFIZER INC.CLEVELAND CLINIC HOSPITAL$200A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-07-08American RegentCLEVELAND CLINIC FOUNDATION$9,550Heart_FID2019
2019-06-04PFIZER INC.CLEVELAND CLINIC HOSPITAL$195A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-04-11PFIZER INC.CLEVELAND CLINIC HOSPITAL$234A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-04-11PFIZER INC.CLEVELAND CLINIC HOSPITAL$1,300A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-04-10American RegentCLEVELAND CLINIC FOUNDATION$12,200Heart_FID2019
2019-04-09PFIZER INC.CLEVELAND CLINIC HOSPITAL$1,500A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-04-09PFIZER INC.CLEVELAND CLINIC HOSPITAL$234A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-04-09PFIZER INC.CLEVELAND CLINIC HOSPITAL$1,500A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019
2019-03-13American RegentCLEVELAND CLINIC FOUNDATION$333Heart_FID2019
2019-01-21American RegentCLEVELAND CLINIC FOUNDATION$5,000Heart_FID2019
2019-01-03PFIZER INC.CLEVELAND CLINIC HOSPITAL$2,821A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Cuyahoga CountyIndependence city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Independence, OH, county Cuyahoga County, OH, state Ohio; placed by its city name.

MeasurePlace (city or town)
Independence, OH
County
Cuyahoga County, OH
State
Ohio
Population B010037,5341,245,87311,810,293
Population, 2020 census P17,5841,264,81711,799,448
Median age B0100248.440.439.7
Under 18 B0100119.2%20.5%22.0%
65 and over B0100125.5%19.5%18.3%
Households B110013,121554,5514,863,191
Foreign born B050023.1%7.7%5.2%
Median household income B19013$115,733$64,468$71,389
Median family income B19113$126,413$89,252$92,749
Per capita income B19301$58,711$42,747$40,552
Poverty rate B170012.4%16.1%13.3%
Unemployment rate B230251.5%6.6%4.8%
Civilian labor force B230254,068650,5775,994,779
Mean commute (minutes) B0801322.623.323.4
Bachelor's degree or higher B1500347.4%36.5%31.5%
Housing units B250013,217615,3315,292,391
Owner-occupied B2500390.4%59.4%67.2%
Renters B250039.6%40.6%32.8%
Median home value B25077$309,900$195,400$214,800
Median gross rent B25064$1,383$1,060$1,034
White, not Hispanic B0300292.4%56.5%75.8%
Black B030021.8%28.5%12.0%
Hispanic or Latino B030021.3%7.0%4.8%
Asian B030021.4%3.3%2.5%
American Indian and Alaska Native B030020.0%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Independence, OH.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.